FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295126421> ?p ?o ?g. }

• W4295126421 endingPage "457" @default.
• W4295126421 startingPage "446" @default.
• W4295126421 abstract "The development of multi-dose, subunit vaccine formulations can be challenging since antimicrobial preservatives (APs) often destabilize protein antigens. In this work, we evaluated Human Papillomavirus (HPV) Virus-Like Particles (VLPs) to determine if combining different APs used in approved parenteral products, each at lower concentrations than used alone, would maintain both antimicrobial effectiveness and antigen stability. To identify promising AP combinations, two different screening strategies were utilized: (1) empirical one-factor-at-a-time (OFAT) and (2) statistical design-of-experiments (DOE). Seven different APs were employed to screen for two- and three-AP combinations using high-throughput methods for antimicrobial effectiveness (i.e., microbial growth inhibition assay and a modified European Pharmacopeia method) and antigen stability (i.e., serotype-specific mAb binding to conformational epitopes of HPV6, 11, 16 VLPs by ELISA). The OFAT and DOE approaches were complementary, such that initial OFAT results (and associated lessons learned) were subsequently employed to optimize the combinations using DOE. Additional validation experiments confirmed the final selection of top AP-combinations predicted by DOE modeling. Overall, 20 candidate multi-dose formulations containing two- or three-AP combinations were down-selected. As described in Part 2 (companion paper), long-term storage stability profiles of aluminum-adjuvanted, quadrivalent HPV VLP formulations containing these lead candidate AP combinations are compared to single APs." @default.
• W4295126421 created "2022-09-11" @default.
• W4295126421 creator A5000714481 @default.
• W4295126421 creator A5005091169 @default.
• W4295126421 creator A5008194289 @default.
• W4295126421 creator A5013065825 @default.
• W4295126421 creator A5017925928 @default.
• W4295126421 creator A5018097676 @default.
• W4295126421 creator A5019976375 @default.
• W4295126421 creator A5026833623 @default.
• W4295126421 creator A5028003165 @default.
• W4295126421 creator A5035149462 @default.
• W4295126421 creator A5043166283 @default.
• W4295126421 creator A5063380862 @default.
• W4295126421 creator A5065112517 @default.
• W4295126421 creator A5070321614 @default.
• W4295126421 creator A5072784089 @default.
• W4295126421 creator A5073302681 @default.
• W4295126421 creator A5075522646 @default.
• W4295126421 creator A5091793372 @default.
• W4295126421 date "2023-02-01" @default.
• W4295126421 modified "2023-09-23" @default.
• W4295126421 title "Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part I - Screening of Preservative Combinations" @default.
• W4295126421 cites W1586957091 @default.
• W4295126421 cites W1973633538 @default.
• W4295126421 cites W1981076153 @default.
• W4295126421 cites W2014837879 @default.
• W4295126421 cites W2040700588 @default.
• W4295126421 cites W2046077398 @default.
• W4295126421 cites W2070642362 @default.
• W4295126421 cites W2072331921 @default.
• W4295126421 cites W2079910321 @default.
• W4295126421 cites W2091279113 @default.
• W4295126421 cites W2091775298 @default.
• W4295126421 cites W2101781338 @default.
• W4295126421 cites W2114031476 @default.
• W4295126421 cites W2128900064 @default.
• W4295126421 cites W2143277207 @default.
• W4295126421 cites W2148799106 @default.
• W4295126421 cites W2338720989 @default.
• W4295126421 cites W2584855429 @default.
• W4295126421 cites W2587904144 @default.
• W4295126421 cites W2613991118 @default.
• W4295126421 cites W2806356939 @default.
• W4295126421 cites W2946893685 @default.
• W4295126421 cites W3082261970 @default.
• W4295126421 cites W4288809661 @default.
• W4295126421 doi "https://doi.org/10.1016/j.xphs.2022.09.001" @default.
• W4295126421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36096284" @default.
• W4295126421 hasPublicationYear "2023" @default.
• W4295126421 type Work @default.
• W4295126421 citedByCount "0" @default.
• W4295126421 crossrefType "journal-article" @default.
• W4295126421 hasAuthorship W4295126421A5000714481 @default.
• W4295126421 hasAuthorship W4295126421A5005091169 @default.
• W4295126421 hasAuthorship W4295126421A5008194289 @default.
• W4295126421 hasAuthorship W4295126421A5013065825 @default.
• W4295126421 hasAuthorship W4295126421A5017925928 @default.
• W4295126421 hasAuthorship W4295126421A5018097676 @default.
• W4295126421 hasAuthorship W4295126421A5019976375 @default.
• W4295126421 hasAuthorship W4295126421A5026833623 @default.
• W4295126421 hasAuthorship W4295126421A5028003165 @default.
• W4295126421 hasAuthorship W4295126421A5035149462 @default.
• W4295126421 hasAuthorship W4295126421A5043166283 @default.
• W4295126421 hasAuthorship W4295126421A5063380862 @default.
• W4295126421 hasAuthorship W4295126421A5065112517 @default.
• W4295126421 hasAuthorship W4295126421A5070321614 @default.
• W4295126421 hasAuthorship W4295126421A5072784089 @default.
• W4295126421 hasAuthorship W4295126421A5073302681 @default.
• W4295126421 hasAuthorship W4295126421A5075522646 @default.
• W4295126421 hasAuthorship W4295126421A5091793372 @default.
• W4295126421 hasBestOaLocation W42951264211 @default.
• W4295126421 hasConcept C104317684 @default.
• W4295126421 hasConcept C126322002 @default.
• W4295126421 hasConcept C147483822 @default.
• W4295126421 hasConcept C159047783 @default.
• W4295126421 hasConcept C185592680 @default.
• W4295126421 hasConcept C203014093 @default.
• W4295126421 hasConcept C2776387124 @default.
• W4295126421 hasConcept C2994532551 @default.
• W4295126421 hasConcept C31903555 @default.
• W4295126421 hasConcept C40767141 @default.
• W4295126421 hasConcept C4937899 @default.
• W4295126421 hasConcept C55493867 @default.
• W4295126421 hasConcept C67031304 @default.
• W4295126421 hasConcept C71924100 @default.
• W4295126421 hasConcept C86803240 @default.
• W4295126421 hasConcept C89423630 @default.
• W4295126421 hasConceptScore W4295126421C104317684 @default.
• W4295126421 hasConceptScore W4295126421C126322002 @default.
• W4295126421 hasConceptScore W4295126421C147483822 @default.
• W4295126421 hasConceptScore W4295126421C159047783 @default.
• W4295126421 hasConceptScore W4295126421C185592680 @default.
• W4295126421 hasConceptScore W4295126421C203014093 @default.
• W4295126421 hasConceptScore W4295126421C2776387124 @default.
• W4295126421 hasConceptScore W4295126421C2994532551 @default.
• W4295126421 hasConceptScore W4295126421C31903555 @default.
• W4295126421 hasConceptScore W4295126421C40767141 @default.

• next